NEJM and The Lancet issue expressions of concern as researchers question where the company got its data on thousands of coronavirus patients.

Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.

A paper published in The Lancet reported that hospitalized COVID-19 patients taking the drug had a higher risk of death, although some researchers have raised questions about the data.

The idea of deliberately infecting volunteers with SARS-CoV-2 has garnered significant attention as a potential avenue to speedier development, as the World Health Organization weighs in with recommendations.

Gilead’s experimental antiviral drug shortened the average time it took COVID-19 patients to recover in a NIAID-sponsored trial. There was weak evidence that it also helped reduce deaths.

The report by Didier Raoult and colleagues that examined the use of the anti-malarial drug in a small number of COVID-19 patients receives criticism from the very society that published it.

The first volunteer will receive a shot of the synthetic RNA vaccine today.

The WHO chief calls for swift action as universities in multiple countries shut down and researchers report kids can become infected.

Aripiprazole, marketed as Abilify, is widely thought to be safer than risperidone, the only other drug approved for use in autistic children. A decade’s worth of data suggests that is not true.